Posted on

DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves

TOKYO, Jan 30, 2023 - (JCN Newswire via SEAPRWire.com) - NTT DOCOMO, INC. announced today that in collaboration with YKK AP Inc. it has launched a demonstration test to verify the radio-wave penetration characteristics of signal-permeable windows made with a light, porous material called aerogel, aiming to improve indoor reception of external radio waves while maintaining the insulation benefits of windows.High-performance materials, multilayered window glass and Low-E glass are being used more widely to improve the insulation of homes and offices for energy efficiency. As a consequence, however, it is becoming more difficult for high-frequency radio waves used by cellphones and other applications to reach indoor spaces. In response, DOCOMO and YKK AP are developing windows that allow radio waves to pass through easily while still maintaining high-performance thermal insulation. The plan is eventually to install such windows in the ceilings and walls of existing as well as new homes and offices.DOCOMO and YKK AP will now test a prototype window made with aerogel, a high-performance thermal-insulation gel-like material, to confirm its radio-wave penetration characteristics. Aerogel is known to have a dielectric constant close to that of air and allows radio waves to penetrate easily. The demonstration will enable DOCOMO to test materials, shapes and window structures that best allow radio waves to pass through.Going forward, DOCOMO will continue to work toward 5G Evolution & 6G by researching and developing technologies including windows easily penetrated by high-frequency millimeter and terahertz radio waves for high-quality indoor connectivity.The initiative will be introduced during "docomo Open House '23," which will be held online from Thursday, February 2 through the rest of the month. Please visit:www.docomo.ne.jp/english/corporate/technology/rd/openhouse/openhouse2023/About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. www.docomo.ne.jp/english/. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)

Bozeman, MT, December 29, 2022 – (SEAPRWire) – Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in Leukemia patients. Alercell is on a mission of making a significant difference in the fight against cancer by offering unique and precise diagnostic solutions that enhance patient outcomes. Alercell is a young and dynamic firm. To better fulfill the demands of the clients, they are continually working to improve their products and services. They have an active research and development program to create new goods for even more precise testing, and their products are based on the most recent technology. Alercell, Inc. seeks to provide innovative in-vitro testability for cancer testing while streamlining the process of detecting infectious diseases. In their ideal world, early disease detection is achieved by testing, allowing prompt implementation of preventative measures. Alercell is based in the United States, but they also have manufacturing and storage facilities in Europe and Asia, extending its accessibility and reach around the globe. In July 2020, the first Alercell COVID-19 fast test arrived in the USA. Since then, Alercell has created a stir in the sector by creating new, creative methods for conducting tests that are more precise, effective, and easily accessible. Being a molecular diagnostics startup, Alercell, Inc. also offers quick testing for leukemia and cancer to detect life-threatening conditions as soon as possible. The company was established to give cancer patients worldwide better precise and rapid diagnostic tools. By offering unique and accurate diagnostic solutions that enhance patient outcomes, Alercell aims to contribute to the fight against cancer. “Stopping it before it starts” is the cornerstone of the Alercell mission. Our genetic testing is the first defense against cancer, leukemia, and infectious diseases. Bozeman, Montana-based Alercell is a biotechnology business with a R&D branch in New York City. Alercell will soon introduce a new test and brand. The first leukemia diagnostic test, LENA Q51®, was based on DNA sequencing and could identify up to 51 gene alterations in leukemia patients. An intriguing development is this test. Until recently, a series of blood tests and a bone marrow biopsy were required when someone was “suspected” to have leukemia. It costs thousands of dollars and takes somewhere between 6 and 9 weeks. With LENA Q51®, all of this is avoided, and in just three hours using a qPCR machine, clinicians will be able to identify any gene mutations among 51 different genes. By doing this, we can determine in 3 hours via computer, eliminating the need for human interpretation; the information gathered will also enable us to tailor the patient’s treatment—all of this for a much lower price. Moreover, the fight against the most lethal cancer, lung cancer in the US is a first. The first methylation-based molecular diagnostic test for lung cancer, LENA S1®, will be made available by Alercell later in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present. Alercell Neuroscience will make a formal announcement in early 2023. Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity. Prof. Gleb Sukhorukov, Ph.D., Chair in Biopolymers at the School of Engineering and Materials Science, Queen Mary University of London (QMUL), will spearhead our efforts. Professor Sukhorukov is a renowned scientist around the globe. Alercell plays a significant role in preventative medicine, particularly in the detection and treatment of cancer. The CEO and the CMO of the company, Dr. Alexandre Scheer MD, are leveraging genetic research to develop novel drugs and testing procedures. Scheer thinks that genetic science holds the answer to improving early diagnosis and eventually identifying severe illnesses before they manifest inside the body. By employing such techniques, the healthcare system may save a large sum of money, and patients may receive excellent care before grueling chemotherapy treatments. Scheer is particularly sensitive to this subject since he is undergoing all these challenging therapies while battling severe cancer. Frederic Scheer stated, “I want to let people know well in advance to avoid what I am going through”. Alercell, Inc. co-founder Frederic Scheer successfully floated multiple start-up firms on stock-exchanges including NASDAQ and NYSE. For the past 25 years, he has worked in the chemical business and alternative technology. Scheer holds 15 US biotechnology patents including three on nanoparticles. As the co-founder of Alercell Inc. “I am thrilled that via the application of our knowledge of the genome, we are now able to produce very performing tests that will help people in finally avoiding the unpleasant traditional treatment,” he says regarding the company’s goods. The business focuses on collaborating with reputed pharmaceutical firms and other healthcare organizations to benefit its patients and ensure that the public always has access to the quickest diagnostic procedures and most affordable medications.” Media Contact Brand: ALERCELL, INC. Contact: Frederic Scheer E-Mail: fscheer@alercell.com Website: https://alercell.com SOURCE: ALERCELL The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

Read More
Posted on

MHI Delivers Testing Equipment for Safety Demonstration of Nuclear Fusion Blankets for ITER in Southern France

TOKYO, Jul 6, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of testing equipment to the Rokkasho Fusion Institute in Aomori Prefecture, part of Japan's National Institutes for Quantum Science and Technology (QST), to confirm and demonstrate the safety of the "blanket," a core component of a nuclear fusion reactor. The blanket system being developed at this research center will be used as Japan's Test Blanket Module (TBM) for the ITER-TBM project, the world's first test of blanket systems in an actual reactor environment, at ITER(1), the experimental fusion reactor currently under construction in southern France. Following the delivery of testing equipment, MHI has strong intention to contribute to the development of a blanket system for the ITER-TBM project through providing other systems/components such as TBMs.The testing equipment supplied by MHI comprises four systems, the High Heat Flux Test Equipment, In Box Water Eruption Test Equipment, Be-Water Reaction Test Equipment, and Flow Assisted Corrosion Test Loop. These testing systems will be used for various experiments aimed at developing a blanket system for the ITER-TBM project, and to confirm its safety. The blanket is one of the components that comprises the inner wall of the fusion reactor. It is a critical component that extracts the heat generated by the reactor, as well as provides for breeding and self-sustainment(2) of tritium, which is used as fuel.ITER is an international megaproject to demonstrate, both scientifically and technologically, the feasibility of fusion energy. ITER-TBM is a project to conduct functional demonstration testing of different TBM systems, each developed independently by four of the seven participating parties (Japan, the EU, the U.S., Russia, South Korea, China, and India). Because the results from this project will influence the relative merits of blanket systems for commercial reactors in the future, each country is actively developing TBMs with demonstrated functionality and safety. In Japan, QST, as the domestic agency for the ITER Project, is leading the development of the country's blanket system.MHI was previously awarded contracts from QST for manufacture of core components for ITER, including five (of a total of 19) toroidal field (TF) coils(3), four of which have been shipped, and six units of the divertor outer vertical targets(4), which are currently being manufactured. MHI will continue to actively support the ITER project to develop this technology, which will be vital to the stable development of the world, and contribute to the realization of fusion energy.(1) Fusion is the energy source that enables the sun to keep shining. The ultimate goal is achieving fusion on Earth. Fusion reactions fuse light atomic nuclei (deuterium and tritium) in a plasma environment into the heavier element of helium. Fusion reactions emit zero carbon dioxide, and their source of fuel can be extracted from seawater in virtually unlimited quantities (lithium from which tritium is derived, and deuterium). Fusion energy is expected to provide fundamental solutions to many of the world's energy and environmental problems.(2) Fusion reactors use deuterium and tritium as fuel. Neutron irradiation of a lithium compound in the blanket is used to produce and supplement the tritium that is consumed in the reaction process (self-sustainment).(3) For details on the TF coils for ITER that QST ordered from MHI, see the following press release. www.mhi.com/news/210524.html4For details on the divertor outer vertical targets for ITER that QST ordered from MHI, see the following press release. www.mhi.com/news/211213.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

MHIENG to Perform CO2 Capture Demonstration Test at Operating Cement Plant in Japan

TOKYO, Mar 30, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries Engineering, Ltd. (MHIENG), a group company of Mitsubishi Heavy Industries, Ltd. (MHI), has signed a memorandum of understanding (MOU) with Tokuyama Corporation, one of Japan's leading chemicals/cement manufacturers, on the implementation of a CO2 capture demonstration testing program at their cement plant. This program will take place for a period of nine months commencing in June 2022, and will be the MHIENG's first implementation to perform demonstration test at a cement plant in operation.Tokuyama's Nanyo Plant (Photo provided by Tokuyama Corp.)A mobile CO2 capture test unit manufactured by MHIENG is being installed at Tokuyama's existing cement plant in Shunan, Yamaguchi Prefecture, where Tokuyama is based. Flue gas from cement kiln, which contains CO2 and other components would be introduced to the mobile unit for the demonstration test. MHIENG will evaluate its performance and study optimum technology and design suited for cement application. These insights will enable MHIENG to realize CO2 capture in the cement industry, and will also contribute to achieving the industry's decarbonization goals.MHIENG's CO2 capture technology has already been successfully used in commercial applications at chemical and coal fired power plants, and MHIENG has many experiences of conducting demonstration tests for industrial fields such as in biomass-fueled power plants and waste-to-energy plants. With this first demonstration test in a cement plant, MHIENG will acquire profounder expertise and knowledge of its technology, which will realize stable and continuous CO2 capture with optimized process. MHIENG's robust operational track record, resulting data and expertise will further accelerate the carbon neutrality in diverse industrial fields both within Japan and around the world.Besides cement production, Tokuyama is also known for various products in the areas of chemical, life science and the environment. Tokuyama is very proactive in promoting the development of products and technologies that solve the issues the society faces, such as global warming. The demonstration test agreed under this MOU is part of Tokuyama's commitment to implement specific measures to enable a carbon-neutral society.MHI Group is currently strengthening its position in the energy transition, and development of a CO2 ecosystem is central to those initiatives. Carbon capture, utilization and storage (CCUS) is garnering attention as an effective means for realizing carbon neutral society. Going forward, MHIENG will continue to contribute toward reducing greenhouse gas emissions on a global scale by promoting broad adoption of high-performance CO2 capture technology worldwide. It will also press ahead in developing new proprietary technologies to protect the global environment.About MHIENG's CO2 capture technologyMHIENG (originally MHI), together with The Kansai Electric Power Co., Inc., has been developing CO2 capture technologies -- KM CDR Process and Advanced KM CDR Process -- since 1990. As of March 2022, MHIENG has delivered 13 plants adopting the KM CDR Process, and three more are under construction, making MHIENG a global leader in this field.For further information, see: https://www.mhi.com/products/engineering/co2plants.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Yeahka Donate 60,000 Antigen Rapid Test Kits Supporting Hong Kong’s Fight Against COVID-19

HONG KONG, Mar 3, 2022 - (ACN Newswire via SEAPRWire.com) - Yeahka Limited ("Yeahka" or the "Company") (09923.HK) has announced a donation of 60,000 antigen rapid test kits to support Hong Kong's fight against the increasingly serious outbreak of Covid-19.The antigen rapid test kits will be donated to Po Leung Kuk and distributed to the elderly and disabled through its elderly service units and rehabilitation service units respectively, helping them monitor their health status in real time. The fifth wave of the pandemic has proven challenging for Hong Kong, with the number of new daily COVID-19 infections hitting record highs. In the face of the severe pandemic situation, there is an increase in demand for pandemic prevention resources. Yeahka has been closely monitoring the pandemic situation in Hong Kong and hopes the initiative will help, sending love and care to the people in need. About YEAHKA LIMITED (Stock Code: 9923.HK)Yeahka, listed on the Main Board of Hong Kong Stock Exchange in 2020, is a leading payment-based technology platform dedicated to creating value for merchants and consumers by providing one-stop payment services and diversified technology-enabled business services. According to Analysys's report in 2022, Yeahka ranks No.1 in the non-bank, Independent QR code payment service market in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Mitsubishi Shipbuilding Concludes Agreement on Construction of World’s First Demonstration Test Ship for Liquefied CO2 Transportation

TOKYO, Feb 2, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Shipbuilding Co., Ltd., a Yokohama-based member of Mitsubishi Heavy Industries (MHI) Group, has concluded a contract with Sanyu Kisen Co., Ltd., a Kobe-based enterprise principally engaged in management of ships navigation in Japanese as well as foreign waters, calling for the construction of a demonstration test ship to transport liquefied carbon dioxide (LCO2) in conjunction with initiatives of the New Energy and Industrial Technology Development Organization (NEDO) in "CCUS R&D and Demonstration Related Project / Large-scale CCUS Demonstration in Tomakomai / Demonstration Project on CO2 Transportation / R&D and Demonstration Project for CO2 Marine Transportation" (the demonstration projects). Construction will get underway at the Enoura Plant of MHI's Shimonoseki Shipyard & Machinery Works, with completion and delivery scheduled for the second half of the fiscal 2023.Conceptual image of the LCO2 demonstration test shipThe Engineering Advancement Association of Japan (ENAA), one of the entities performing business relating to the demonstration projects, will charter the ship from Sanyu Kisen, the subcontractor, and operate it for the project purposes. Under consignment from ENAA, three additional project partners - Kawasaki Kisen Kaisha, Ltd. ("K" LINE), Nippon Gas Line Co., Ltd., and Ochanomizu University - will accelerate R&D of the LCO2 transportation technology and contribute to cost reduction of CCUS technology and safe, long-distance and large-scale transportation of LCO2.Although ships to carry LCO2 used in the food industry have previously been constructed and operated in Europe and Japan, the ship to be newly constructed is expected to be the world's first LCO2 carrier intended specifically for CCUS. Mitsubishi Shipbuilding will be in charge of all aspects from the ship design through construction, including the cargo containment system, applying its gas handling technologies and expertise cultivated through the construction of liquefied gas carriers (both LPG and LNG types).CCUS is garnering attention today as an effective means of achieving a carbon-neutral society. Because CO2 emissions sites are often located distant from the sites selected for carbon utilization or storage, demand is expected to increase for LCO2 carriers which can transport their cargo safely and economically. Through the experience to be gained by constructing the world's first LCO2 carrier built specifically for CCUS, MHI Group will strengthen its current strategic business focused on the energy transition. The Company will also continue its dedication to developing and providing the technologies relating to LCO2 carriers necessary for CCUS value chain building, to contribute to CO2 ecosystem development.Mitsubishi Shipbuilding, under its "MARINE FUTURE STREAM" growth strategy, has set two overarching targets: decarbonization through innovative technologies in maritime industry such as use of renewable energies and carbon recycling, and effective use of ocean spaces through autonomous operation and electrification. To achieve those goals, the company aims to pursue and realize diverse innovations applicable to the industry. The ongoing development of LCO2 carriers and active quest for commercial viability in this area are part of those initiatives, with the company's ultimate goal set on realizing decarbonization as a marine system integrator.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Labnovation’s COVID-19 ART Test Kit, Imported by Clearbridge, is One of the Only Two COVID-19 ART Test Kits in the Philippines Approved by the FDA of the Philippines for Self-Testing

Singapore, Jan 26, 2022 - (ACN Newswire via SEAPRWire.com) - Asia's integrated healthcare company, Clearbridge Health Limited ("Clearbridge" or the "Company" and together with its subsidiaries, the "Group"), is pleased to announce that Labnovation Technologies, Inc.'s ("Labnovation") COVID-19 Antigen Rapid ("ART") Test Kit, which is imported by Clearbridge and registered for use in the Philippines, has been recently approved by the Food and Drug Administration ("FDA") of the Philippines for self-testing. Highlights:- The Group is currently the only approved importer of Labnovation's COVID-19 ART Test Kit in the Philippines as the Group has submitted and obtained the relevant regulatory approval for the ART Test Kit to be imported and used in the country- There are currently only two COVID-19 ART Test Kits, one by Labnovation and the other by Abbott Panbio, that have been recently approved by the FDA of the Philippines for self-testing - Potential for the Group to work with various channel partners and point-of-care networks (such as clinics and pharmacies) in the Philippines to market and distribute Labnovation's COVID-19 ART Test Kit across the country - The Philippines has a population of approximately 110 million and according to the WHO, there are currently more than 3.4 million confirmed COVID-19 cases in the Philippines(1)On 24 January 2022, the FDA of the Philippines approved two self-administered COVID-19 ART Test Kits, one from Labnovation and one from Abott Panbio, in compliance with the application requirements listed in the FDA Advisory No. 2021-0684 entitled "Guidance on the Process for the Issuance of Special Certification for COVID-19 Test Kits Based on FDA Memorandum No. 2020-006 and FDA Memorandum No. 2021-009." These kits can be used by individuals to detect SARS-CoV-2 antigen from nasal swabs of probable COVID-19 patients(2).To ensure safety, efficacy and quality of these COVID-19 test kits, the FDA of the Philippines also advised the public and stakeholders to source for the COVID-19 test kits from FDA authorized importers including the Group who are holders of the Certification for the COVID-19 test kits or their duly authorized FDA licensed distributors.The Group is currently the only importer and distributor of Labnovation's COVID-19 ART Test Kit in the Philippines as the Group has submitted and obtained the relevant regulatory approval for the ART Test Kit to be used in the country.As a pan-Asian private healthcare group, Clearbridge has built up a business presence and network across regional markets. With deep experience and familiarity working with health authorities, medical supply chain logistic partners and healthcare institutions, the Group has established a procurement and distribution platform that offers a wide range of healthcare products, which includes the Sinopharm COVID-19 vaccine, COVID-19 ART Test Kit, COVID-19 Antibody Test Kit, among others, in Singapore and other countries in the region.Mr. Jeremy Yee, Executive Director and Chief Executive Officer of Clearbridge, said, "In the Philippines, daily cases hit record highs in January following the detection of local cases of the Omicron variant. COVID-19 self-testing is one of the key risk-reduction measures that protect communities and we have seen self-testing becoming a vital part of the pandemic response in various countries.With the approval of Labnovation's COVID-19 ART Test Kit for self-testing in the Philippines, we believe that it can serve as an important tool for routine testing by the public, offering some peace of mind at the same time.We aim to work with various channel partners and point-of-care networks (such as clinics and pharmacies) in the Philippines for Labnovation's COVID-19 ART Test Kit to gain wider market outreach and accessibility."(1) https://covid19.who.int/region/wpro/country/ph (2) bit.ly/3r45gGQAbout Clearbridge Health Limited(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)Aligning with the emerging healthcare trends in Asia, Clearbridge Health Limited is a healthcare group that currently provides a broad base of healthcare solutions via 4 distinctive strategic business units, comprising healthcare systems, medical clinics/centres and strategic medical technology investments, in nexus of high demand across Asia as well as investments within the global healthcare sector that are EBITDA positive or at an inflection point with a clear line of sight to profitability.For more information, please visit us at www.clearbridgehealth.com.Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.Media & Investor Contacts: Mr. Alex TAN Mobile: +65 9451 5252Email: alex.tan@8prasia.comThis press release has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Biolidics to Commence Commercial Production of its ClearEpi SARS-COV-2 Neutralising Antibody Rapid Test Kit

Singapore, Dec 9, 2021 - (ACN Newswire via SEAPRWire.com) - Biolidics Limited ("Biolidics" or the "Company" and together with its subsidiaries, the "Group"), a medical technology company with a focus on innovative diagnostic solutions, is pleased to announce that it had on 8 December 2021: (i) entered into a definitive agreement with its contract manufacturer for the production of the ClearEpi NAB Test; and (ii) obtained the relevant product liability insurance for the ClearEpi NAB Test. The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR's A*ccelerate.Highlights:- Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the "ClearEpi NAB Test") and obtained the relevant product liability insurance- Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research ("A*STAR")'s Accelerate Technologies Pte Ltd ("A*ccelerate"), provides results that may indicate an individual's protective immunity against COVID-19- Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection(1)- The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel(2)), among others- The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector- The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European UnionThe commercial production for the ClearEpi NAB Test by the Company is expected to commence in the current financial year ending 31 December 2021.The clinical validation of the ClearEpi NAB Test was undertaken in Singapore. Biolidics engaged A*STAR Infectious Disease Labs (ID Labs) for the screening of the prototype, as part of the clinical validation of the ClearEpi NAB Test conducted by Biolidics. ID Labs is an A*STAR research institute set up in April 2021 to undertake disease-specific research efforts within A*STAR. On 20 September 2021, the Group announced that it has developed the ClearEpi NAB Test that is intended for qualitative detection of neutralising antibodies in serum or plasma which provides an indication of the individual's protective immunity against COVID-19 infection(1),(3).Most commercially available serology tests against COVID-19, including the Company's COVID-19 Antibody Test Kit launched on 30 March 2020, test for the presence of IgM/IgG antibodies. The presence of IgM/IgG antibodies indicates whether an individual has been previously infected. Not all antibodies have neutralising or "disarming" capacity.Neutralising antibodies, on the other hand bind to regions of the virus that "disarm" or prevent infection directly. The presence of neutralising antibodies provides indications that an individual has protective immunity against infection1,3. Nonetheless, it is important to note that information is still emerging from researches in relation to the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against COVID-19 may last in an individual.In addition, the Group announced on 20 September 2021 that it had received confirmation for the CE marking for the ClearEpi NAB Test which enables the Company to market and sell the ClearEpi NAB Test in the European Union.Mr. Song Tang Yih, Executive Director and Chief Executive Officer of Biolidics, said, "As the COVID-19 pandemic becomes endemic, we believe that our ClearEpi NAB Test canbecome a vital tool in assessing vaccine candidates and formulate vaccine deployment strategies (such as the need for additional booster doses). With our ClearEpi NAB Test, the testing of neutralising antibodies may also serve as a guide for government agencies to accelerate the re-opening of the economy, social activities and global travel."This document is to be read in conjunction with Biolidics' exchange filings on 8 December 2021, which can be downloaded via www.sgx.com.About Biolidics Limited(Bloomberg Code: BLD: Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)Incorporated in 2009, Biolidics Limited is a precision medicine medical technology company with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.Biolidics has developed and commercialised the ClearCell FX1 System, a fully automated CE- IVD medical device which relies on a novel, patented technology to separate and enrich cancer cells from blood, allowing users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.Liquid biopsies (i.e. analysis of the CTCs in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.Biolidics also has a CAP accredited clinical laboratory in Singapore that offers a wide range of tests, which could potentially accelerate its revenue growth and execution of its business strategy in cancer diagnostics.In addition, Biolidics has formed an infectious diseases division to develop certified test kits with various diagnostic partners.Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration.For additional information, please visit www.biolidics.com.This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX- ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.(1) go.nature.com/31HbCSv(2) bit.ly/3EEnO4G(3) bit.ly/3oyqv26Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Man with upper respiratory tract infection unlawfully left home for tattooing session

SINGAPORE - A man who was issued a medical certificate (MC) after he was diagnosed with acute upper respiratory tract infection in a clinic last December decided to skip his Covid-19 swab test and took a bus home. Instead of staying indoors the next day, Tan Fu Yu left his Ang Mo Kio flat and took a private-hire car to a Sin Ming Road tattoo studio to get his chest inked. Tan went for a polymerase chain reaction test for Covid-19 only on Sept 19 this year and tested negative for it. Court documents do not disclose why he took the test about nine months after receiving the MC last December. On Friday (Nov 26), the 20-year-old Singaporean pleaded guilty in a district court to leaving his home without a reasonable excuse despite being given a relevant MC . Deputy Public Prosecutor Jane Lim said that Tan went to Ang Mo Kio Polyclinic at around 3pm on Dec 8 last year to seek treatment for a dry cough and an itchy throat. A doctor later diagnosed him with an acute upper respiratory tract infection and told him to undergo a swab test for Covid-19. The doctor also issued Tan with an MC, excusing him from work or school for three days. The MC also stated that Tan was required by law to stay at home until his swab test showed a negative result. Tan acknowledged the doctor's explanation, collected his MC and left the consultation room. The DPP said: "Instead of going for his Covid-19 swab test and collecting his medications, the defendant left (the polyclinic) and returned to his residence by bus. "The nurse tried to contact the defendant at his mobile phone multiple times, but the calls were unanswered." More on this topic   Related Story 22-year-old woman jailed 3 weeks for breaching Covid-19 order to stay home   Related Story Man on MC who had acute respiratory symptoms allegedly left home, took MRT The next day, Tan left his home and reached the tattoo studio at around 1.40pm. The artist then noticed that Tan was bleeding excessively while getting his chest inked. After the session, Tan left the studio at around 3pm and took a bus home. On Friday, DPP Lim urged the court to give him to a short jail sentence, stressing that he had left his home for a "frivolous reason" - to get a tattoo done. Tan, who was unrepresented, pleaded for a second chance and added: "(There was) no excuse for whatever I did." He will be sentenced on Dec 9. For committing the offence, he can be jailed for up to six months and fined up to $10,000. More on this topic   Related Story Courts & Crime: Read more stories

Read More
Posted on

askST: What is a valid pre-departure ART and how can I book one overseas?

SINGAPORE - As of 11.59pm on Thursday (Nov 11), most travellers can take an antigen rapid test (ART) performed by a trained professional overseas before flying into Singapore. This applies to those returning via the vaccinated travel lane (VTL) and from countries in Categories II and III, which include Australia, Britain and the United States. Previously, all travellers, except those aged two and below, had to take a polymerase chain reaction (PCR) to return and test negative within 48 hours before departure. Travellers now have a longer window to take the tests as a pre-departure test taken any time on Nov 12, for instance, can be valid until 11.59pm on Nov 14. Here is what you need to know about the new measures and how to book an ART overseas. Q: What is a pre-departure Covid-19 test? Do I need to take a test before leaving Singapore and upon arrival? A: The pre-departure Covid-19 test refers to the test travellers take so that they can present results to airline staff at overseas airports before returning to Singapore. As for the test Singapore residents must undergo for most destinations before leaving the Republic, it is recommended that they check the websites of the immigration authorities or embassies of the destination country beforehand. Travellers can also consult Sherpa - a travel data aggregator that provides information on the destination country's restrictions, and requirements for visa application and additional documents. More information can be found at the Sherpa website. Under the VTL, not all countries require travellers from Singapore to take a PCR test before they can enter. For instance, France and Britain do not require one for vaccinated travellers, but others such as the Netherlands, which reclassified Singapore from a low-risk to a very high-risk country on Thursday, will require testing. When Singapore residents return to the Republic, they still have to undergo an on-arrival PCR at Changi Airport or an exit PCR test after serving their stay-home notice, depending on which country they return from. Q: Why is the Government allowing us to take ART now for those countries? A: The Ministry of Health (MOH) announced on Monday (Nov 8) that changes in border measures are aligned with the Covid-19 testing protocols in place in Singapore. Professor Dale Fisher, a senior consultant at the National University Hospital's Division of Infectious Diseases, said that as global travel resumes, requiring all those returning to take a PCR test will be increasingly challenging in terms of logistical arrangements. Prof Fisher, who is also chair of the World Health Organisation's Global Outbreak Alert and Response Network, said: "In 2019, Changi Airport served 68.3 million passengers, which (averages out to) 187,000 per day. Other airports, which have similar volume, may not have the infrastructure to support so many PCR tests. "Imposing such a test will mean taking away time from GPs or trained professionals and putting more demand on Covid-19 laboratories than they can handle." More on this topic   Related Story S'pore eases Covid-19 rules from Nov 10: What you need to know   Related Story askST: What is the electronic SG Arrival Card and who has to submit it? Q: In what form must my pre-departure ART result take? A: According to the Immigration and Checkpoints Authority, the test must be taken within two days before departure at an internationally accredited or recognised laboratory, clinic, or medical facility. The result certificate must be in English and contain the date and time of when the Covid-19 test was taken. It must also bear the name of the testing institution conducting the Covid-19 test. The pre-departure ART must be taken within two days before departure at an internationally accredited or recognised laboratory, clinic, or medical facility. PHOTO: AFP Self-administered ARTs are not allowed. In some countries, medical providers will issue ART results via e-mail, while others, such as Denmark, have a centralised website where test results can be downloaded or printed.  The Straits Times understands that airports generally accept both printed and digital results. In response to queries from ST, Singapore Airlines (SIA) said its website and mobile app have been enhanced to verify digital health credentials and perform entry rule checks. SIA said: "Customers can generate their own boarding passes through these channels if no other travel documents are required, eliminating the need for physical verification at airports." More on this topic   Related Story Travel to and from S'pore without quarantine: How the Vaccinated Travel Lane works   Related Story Demand rises for Covid-19 pre-departure tests as S'pore opens up more VTLs Q: Where can I take a pre-departure ART? A: MOH has a list of clinics for travel from countries such as Malaysia and South Korea. Both have VTL arrangements with Singapore which will start later this month. For travellers who prefer visiting a familiar clinic, Fullerton Health said that corporate clients registered under its Fullerton One programme can visit any of its clinics in five Asian markets, including the Philippines, Indonesia and Hong Kong, while travelling overseas. A Raffles Medical Group spokesman told ST that customers can visit its clinics in Vietnam, where antigen rapid tests are allowed for pre-departure and are certified. With a wider testing window, it is also not necessary to take the ART at the airport, although you can do so at some locations such as Heathrow Airport in Britain and Los Angeles International Airport in the United States. It is possible to take a test at some attractions such as Disneyland Paris and the Dodger Stadium in Los Angeles, California. More on this topic   Related Story Returning S'poreans, PRs and pass holders vaccinated overseas encouraged to upload certificate   Related Story 6 things to know for quarantine-free travel under VTL Q: Should I engage a travel booking company to arrange a test? A: With the Covid-19 situation constantly changing, travel agencies may be able to advise customers on the different requirements of various countries. For instance, although Singapore accepts a pre-departure ART, countries such as South Korea and Australia still require a PCR test. Booking platform Klook said its listings include information about the opening hours of the service provider and the expected time taken for the ART or PCR results. Mr Aaron Wong, 33, who runs travel website The MileLion, said the waiting time for such tests can fluctuate greatly. While visiting Munich, Germany, via the VTL on two occasions, he waited five minutes in line the first time but had to wait for 90 minutes on his second trip. Mr Steven Ler, executive director of UOB Travel Planners, said: "Buying a pre-departure test as part of a bundle makes it easier for employees going on a work trip. "It saves them the hassle of having to submit receipts to their company for reimbursement. And this will also greatly benefit leisure travellers who prefer a coordinated arrangement. " More on this topic   Related Story Over 36,000 passes issued to non-residents to enter S'pore under vaccinated travel lanes   Related Story Travellers may face tighter curbs in Europe with S'pore taken off EU list   Related Stories:  Related Story Singapore, Malaysia to start VTLs for quarantine-free air travel from Nov 29 Related Story S'pore eases Covid-19 rules from Nov 10: What you need to know Related Story Increasing ICU beds for Covid-19 patients may lead to poorer care for others Related Story Why do more men die of Covid-19? Related Story China ramps up Covid-19 controls, warns of severe situation as winter sets in Related Story How does Merck's Covid-19 pill compare with Pfizer's? Related Story Oxford scientists find gene that doubles risk of dying from Covid-19 Related Story What you need to know about the new Covid-19 Delta Plus variant AY.4.2 Related Story What scientists know about the risk of breakthrough Covid-19 deaths Related Story What the future holds for the coronavirus and us

Read More
Posted on

TraceTogether app adds green passes for cleared users to allow quicker entry at places

SINGAPORE - An animated otter against a green background will now show up on the SafeEntry check-in pass of some TraceTogether app users when they clear vaccination and test status checks. In an update on the TraceTogether website at around 10.20am on Thursday (Nov 11), GovTech said this applied to those who are using version 2.11 and above of the app. Those using an older version of the app can update to the latest version. "The green and white passes were designed to enable quick entry at places with Vaccination or Test status checks," said GovTech, adding that the green background will allow staff to see the pass from a distance and clear queues quickly. It said the animated otter will allow venue staff to easily ensure that the person checking in is not using a screenshot. GovTech added: "Plus, what's not to like about a cute floating otter?" In order to get a green background, also known as a green pass, a person must have a green vaccination status on his home screen and a cleared test status where applicable. Those with a green pass simply need to show that page to venue staff, instead of tapping back to their app's home screen. Those who are unvaccinated and do not have a cleared test status will have a white background on their check-in screen, also known as a white pass. They will need to provide reasons or documents to be allowed entry at places that require vaccination or test status checks. White passes will also appear for those who use the group check-in function, said GovTech, citing "privacy and security reasons". In such cases, everyone in the group will need to show staff their vaccination and test status after they have shown the group check-in pass. "We understand this may create inconvenience, but your data privacy and security takes priority," said GovTech. The green and white passes were designed to enable quick entry at places with vaccination or test status checks, said GovTech. PHOTO: TRACETOGETHER/WEBSITE The green and white passes only show when someone checks in using the SafeEntry QR code. Check-ins done by tapping the app against a SafeEntry Gateway Box or SafeEntry Business App will not trigger the display of the passes. Most users on online forum Reddit welcomed the update, with some praising the inclusion of the animated otter. More on this topic   Related Story TraceTogether vaccination status restored after being unavailable to some earlier   Related Story S'pore eases Covid-19 rules from Nov 10: What you need to know "Better late than never, and I like the otter and I like that it's used to make sure it's not a screenshot," wrote one. However, some questioned whether checking in at venues is still necessary. Checking in with SafeEntry first became mandatory on May 12 last year, in order to help contact tracers find close contacts of infected cases quickly. On Monday, Singapore's director of medical services Kenneth Mak was asked whether contact tracing is still being carried out given the high number of daily cases and the goal of living with endemic Covid-19. Associate Professor Mak said at the time that contact tracing is still ongoing, but it is now being done in a more targeted manner, focusing on clusters and locations with vulnerable people.   Related Stories:  Related Story Singapore, Malaysia to start VTLs for quarantine-free air travel from Nov 29 Related Story S'pore eases Covid-19 rules from Nov 10: What you need to know Related Story Increasing ICU beds for Covid-19 patients may lead to poorer care for others Related Story Why do more men die of Covid-19? Related Story China ramps up Covid-19 controls, warns of severe situation as winter sets in Related Story How does Merck's Covid-19 pill compare with Pfizer's? Related Story Oxford scientists find gene that doubles risk of dying from Covid-19 Related Story What you need to know about the new Covid-19 Delta Plus variant AY.4.2 Related Story What scientists know about the risk of breakthrough Covid-19 deaths Related Story What the future holds for the coronavirus and us

Read More
Posted on

HSA probing unauthorised distribution and supply of SG Diagnostics antigen rapid test kits

SINGAPORE - The Health Sciences Authority (HSA) is investigating the unauthorised distribution and supply of antigen rapid test (ART) kits manufactured by Singapore-based company SG Diagnostics. They are meant for professional use in "healthcare settings by healthcare professionals who are trained to administer the test and validate the results", said the authority on Thursday (Oct 14) in response to queries from The Straits Times. The kits should not be used by untrained lay users, who may derive inaccurate results, the HSA said, adding that this could lead to them not getting timely treatment if they have Covid-19, or failing to take necessary precautions to protect themselves and the people around them. SG Diagnostics had urged consumers in an advertisement in ST Classifieds on Tuesday to stop using the product. When ST called the SG Diagnostics hotline listed in the ad, an operator said buyers are advised to return the ART kits to their suppliers and ask for a refund. ST has contacted SG Diagnostics for comment. Sellers had put up listings on e-commerce platforms like Shopee, Lazada and Carousell, pricing a box of two kits at about $18. Listings for group orders were also seen on shopping platform WeBuy. Many of the listings have been taken down. The kits were also seen to be for sale in physical stores like IT retailer Challenger. The HSA said regulatory and enforcement actions under the Health Products Act will be taken against any party involved in unauthorised distribution and supply of the kits. It advised consumers to purchase and use self-administered ART kits approved in Singapore. The list of kits can be found on the HSA's website. For inquiries on returning the kits, consumers should call the SG Diagnostics hotline on 8030-5766 or e-mail info@sgdiagnostics.com More on this topic   Related Story Buyers urged to return SG Diagnostics ART kits meant only for professional use   Related Story Covid-19 survival kit: All your must-haves

Read More
Posted on

Covid-19 testing regimes in Singapore explained

Regular self-testing has been introduced across various sectors as Singapore moves towards living with the coronavirus in the stabilisation phase. Here is what you need to know.  Polymerase chain reaction (PCR) rostered routine testing (RRT) What it is - Regular PCR test, once every seven days or 14 days. - Under the vaccinate or regular test (VoRT) regime, unvaccinated workers on the seven-day PCR rostered routine testing will have to take one additional antigen rapid test (ART) per week. - Those on 14-day PCR rostered routine testing will have to take three additional ARTs every two weeks. Examples of sectors - Covid-19 front-line workers, border front-line workers, construction, marine and process workers, workers living in dormitories. Where can you take a test? - PCR tests are taken at regional swab centres. - ARTs are self-administered, but must be supervised by another trained staff member, or at quick test centres (QTCs) for freelancers or small businesses. Fast & easy testing RRT What it is - Regular ART, once every seven days. -Under the VoRT regime, unvaccinated workers will have to take one additional ART per week. Examples of sectors - Staff working in higher-risk mask-off settings, or have prolonged close contact with customers, or have frequent interactions with the community. These include workers in food and beverage establishments, retail malls, personal care services, supermarkets and last-mile deliveries. - Staff working in healthcare, eldercare and settings with children aged 12 years and below Where can you take a test? - ARTs are self-administered, but must be supervised by another trained staff member, or at QTCs for freelancers or small businesses More on this topic   Related Story More than 1.2 million ART kits set aside for public officers for 8-week rostered routine testing   Related Story $15 antigen rapid testing available at 25 quick test centres islandwide Voluntary time-limited eight-week RRT What it is - Any company that has employees who work on-site and are not already subject to other mandatory testing regimes. Examples of sectors - Any company can apply Where can you take a test? - Workers can take the ARTs at their own convenience. Note: Information accurate as at Oct 3. Source: Ministry Of Health  More on this topic   Related Story What you need to do if you test positive for Covid-19 using ART kit and have no symptoms   Related Story Covid-19 self-test kits: ST checks out 5 to see which is the easiest to use

Read More
Posted on

PSLE candidates in quarantine need to inform school by 12pm, take daily ARTs at 6pm

SINGAPORE - Quarantined pupils who wish to take the Primary School Leaving Examination (PSLE) this year will need to inform the school by 12pm on the day they receive a quarantine order. They will also need to complete a daily antigen rapid test (ART) at 6pm on the day before each paper. These were among more detailed rules provided in a circular issued by the Ministry of Education (MOE) ahead of the first PSLE written paper on Thursday (Sept 30). On Sunday, the ministry and the Singapore Examinations and Assessment Board announced new rules allowing quarantined students and those on approved absence to sit their national examinations. It said then that those on quarantine have to test negative for Covid-19 with a polymerase chain reaction (PCR) test at the start of the quarantine order, and complete a self-swab with ART kits at home and test negative within 24 hours before each examination paper. The circular on Tuesday added that quarantined pupils must wait at home for Certis officers to arrive to administer their entry PCR test. The circular noted that a PCR test takes at least 24 hours to be processed such that the earliest a child will be able to sit the PSLE exam is two days after the day of notification. This means that if a paper is scheduled the day after pupils receive a quarantine order, they will not be able to sit the specific paper but can apply for special consideration through the school. Under special consideration, a candidate will be awarded a projected grade for a particular paper that takes into consideration multiple sources of data, such as the candidate's performance in other papers for that subject and the school cohort's performance in national and school-based exams. The Certis officer will also provide ART kits for candidates to conduct daily ARTs while waiting for their entry PCR test results, said the circular. They will be notified about these results via online portal and app HealthHub or SMS. If the entry PCR test is negative, a child has to take an ART that evening before the paper and photograph the negative ART result. On the day of the paper, the circular said that a pupil will need to show the negative PCR test and a photograph of the ART result to sit the PSLE paper. He has to continue doing ARTs the day before his remaining papers. More on this topic   Related Story Students in quarantine or on approved Covid-19 absence may still take national exams: MOE   Related Story Parents welcome move to allow students in quarantine to take national exams The circular added that quarantined parents may accompany their child to school after satisfying the same requirements. It reiterated that candidates have to travel directly to the exam venue by private transport or on foot, with no stops in between. Those who are positive for Covid-19 or on stay-home notice are still not allowed to sit exams this year. More on this topic   Related Story Parents anxious over rise in Covid-19 cases among children but attendance normal at pre-schools, tuition centres   Related Story What to do if you have tested positive for Covid-19: 10 important steps

Read More
Posted on

Covid-19 self-test kits: How do they differ?

SINGAPORE - Antigen rapid test (ART) kits for use at home have been flying off the shelves as self-testing ourselves for Covid-19 becomes a regular part of people's lives at work, school and home. The Straits Times checks out the various kits out there to find out how easy each of them are to use. The kits cost between $8 and $13 apiece, with a lower per-kit price for larger packs. Abbott PanBio Covid-19 Antigen Self-Test ST PHOTO: HILLARY TAN Wait time for results: 15 minutes Number of rotations in each nostril: Five Available at: Most major pharmacies The biggest difference with this kit is that the buffer solution comes in a separate container, and must be transferred into a dropper tube before use. The instructions also specify that the swab stick must be broken at the break line and left inside the tube before sealing and dripping the solution onto the test device. Our review: The Abbott PanBio test is great for home use. The separate packaging for the buffer liquid keeps things very hygienic, and the steps are clear and easy to follow. However, the packaging is stiff and not the easiest to use. I find the process more finicky and messier, which could make them more challenging for younger children and those with limited mobility to use. Quidel QuickVue At-Home OTC Covid-19 Test ST PHOTO: HILLARY TAN Wait time for results: 10 minutes Number of rotations in each nostril: At least four Available at: Most major pharmacies After swabbing, the user is required to leave the swab stick in the solution for a minute. Unlike other kits on the market, this one does not require the user to drip the solution onto a test device; instead the device is put into the solution. The results are also read differently. While most kits reflect a positive result by having two visible pink lines, this one displays a pink line close to the blue control line to indicate a positive result. This kit is also the fastest in producing the result, at just 10 minutes. Our Review: This was my favourite kit. I preferred inserting the test device into a bottle to having to drip the sample onto a test device, as it reduces margin of error, and I am less likely to create a mess. Plus, a result displayed with two differently coloured lines is less ambiguous, and easier to explain to children and the elderly. One gripe? I do wish the test strip was less flimsy. SD Biosensor SARS-CoV-2 Antigen Self-Test Nasal ST PHOTO: HILLARY TAN Wait time for results: 15 minutes Number of rotations in each nostril: Four Available at: Selected pharmacies The kits by SD Biosensor are the most compact. They include a desiccant package within the same pouch. If its beads are yellow, the kit is usable, but green beads indicate that the test is no longer valid. Our Review: Having the desiccant package gave me peace of mind, knowing for sure that the test kit was valid. The kit was simple to use and instructions were clear. Most importantly, this kit only required four rotations in each nostril, keeping the process quick and reducing the discomfort. SD Biosensor Standard Q Covid-19 Ag Home Test ST PHOTO: HILLARY TAN Wait time for results: 15 minutes Number of rotations in each nostril: 10 Available at: Most major pharmacies This kit also includes the desiccant package within the same pouch as the test device to reflect if the kit is valid for use. Out of all the kits we tested, this one required the most number of rotations in each nostril. Our Review: This kit was the easiest to acquire, and was easy to use. However, given that most of the other kits only required four or five rotations per nostril, I found this one, which requires 10, to be slightly more uncomfortable. BD Kit for Rapid Detection of Sars-CoV-2 ST PHOTO: HILLARY TAN Wait time for results: 15 minutes Number of rotations in each nostril: Five Availability: Given out in schools; currently not available over the counter The packaging is the most integrated and easiest to keep organised, with the dropper nozzle already attached on the side of the sample collection tube. Instructions are in the four major languages: English, Malay, Tamil and Chinese. The main difference in the testing process for this kit is that the swab must be left in each nostril for an extra five seconds, on top of the five rotations. BD has an identical test kit, packaged differently for retail, on The Health Sciences Authority's (HSA) list. The BD Veritor At-Home Covid-19 Test, however, is currently not circulated in Singapore. Our Review: I thought this kit was the most portable and easy to keep organised . The attached dropper cap prevented me from losing parts of the kit and the larger test device felt sturdier than the others. That said, I did not enjoy having to keep the swab in my nostril for an additional five seconds after rotating it - it made my eyes water a bit more than with the other kits. More on this topic   Related Story What you need to do if you test positive for Covid-19 using ART kit and have no symptoms   Related Story What should I do if I get Covid-19 but MOH has not called me? After trying all the kits approved for use in Singapore, I would definitely use any of them again, and will do so regularly to ensure my health and safety. Overall, they were generally very similar, and all were fairly easy to use. Should you test positive or invalid on an ART test twice, take a photograph of your test results with your identification document in the same photo. You can then dispose of the test kit. Call your nearest Swab and Send Home (Sash) clinic to make an appointment for a confirmatory polymerase chain reaction (PCR) test, and bring this photo along. Do not take public transport there or back. For more information, visit the Ministry of Health's FAQ page.   Related Stories:  Related Story Testing positive for Covid-19: Where do you seek help and what kind of treatment do you need? Related Story Chinese city Harbin orders spas, mahjong salons to shut after Covid-19 case confirmed Related Story Thailand okays injecting Covid-19 vaccine under skin instead of in muscle to stretch supplies Related Story Bats in Laos caves found to carry coronaviruses that share key feature with Sars-CoV-2 Related Story Thousands of Covid-like infections show risk of next pandemic: Study Related Story Governments face tough call on risky reopenings as Covid-19 persists Related Story Let us buy Covid-19 vaccines, pleads Africa Related Story When Covid-19 stole their sense of smell, these experts lost their careers Related Story Britain and neighbours set out paths for coping with Covid-19 Related Story 'My saviour': Hanoi's tiny balconies a refuge in Covid-19 lockdown

Read More
Posted on

Indonesia honored to host MotoGP pre-season at Mandalika

Lombok, Indonesia, Aug 29, 2021 - (ACN Newswire via SEAPRWire.com) - Indonesia is honored to host the MotoGP pre-season test at the Mandalika Circuit, Lombok, West Nusa Tenggara, on February 11-13, 2022, Chief Strategic Communication Officer of the Mandalika Grand Prix Association (MGPA) Happy Harinto stated.Flyer of MotoGP Pre-season on February 11-13, 2022 at Mandalika Circuit. (ANTARA/HO/rst)"It is an honor for the Mandalika circuit, and for Indonesia, to be able to serve as a location for the pre-season test in 2022," Harinto told ANTARA on Saturday.Although counted as a new circuit, the Mandalika Circuit has also joined the World Superbike calendar as the host of the closing series on November 12-14 this year.Harinto believes this is an extraordinary opportunity for Indonesia, since not all countries can be trusted as locations for holding pre-season tests. Various aspects are tested during the pre-season test, starting from the physical racers, motorbikes, engines, chassis, tires, to clothes and helmets."Hence, basically everything is being tested from drivers to test technicians, so later standardization or technological specifications will be applied during the 2022 racing season," he stated. Most importantly, all MotoGP riders along with manufacturers and partners will come to the Mandalika circuit, he remarked.Harinto noted that this is an Indonesian automotive asset which will attract the world's attention. Indonesia should be able to take a cue from automotive industries of other countries."Hopefully, the future of Indonesia's automotive industry will be brighter," he emphasized. "This is an encouragement not only for the automotive, but also the tourism industry. We should package and manage the presence of a MotoGP class world event properly."Prior to Mandalika, MotoGP had scheduled a pre-season test at the Sepang International Circuit in Malaysia on February 5-6. The shakedown test session will also be held from January 31 to February 2 in Sepang, with attendees comprising test riders and rookies.After testing the latest motorcycle package in Malaysia, the racers will head to Lombok, West Nusa Tenggara (NTB).Reporter: Nanien Y, Resinta SEditor: Sri HaryatiCopyright (c) ANTARA 2021 Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

16 quick test centres for Covid-19 set up in S’pore, 4 more planned

SINGAPORE - Sixteen Covid-19 quick test centres have been set up here since they were first announced about a month ago, and four more are on the way as Singapore ramps up its testing capabilities to curb the spread of the coronavirus. The Health Promotion Board (HPB) - the national agency supporting Covid-19 testing - told The Straits Times  on Friday (July 23) that each centre has a daily testing capacity between 400 and 1,000, depending on its size. This means that at least 6,400 tests can take place at these centres each day. HPB said that between June 21 and last Wednesday, about 13,900 tests were conducted at these 16 centres. They are located in Ang Mo Kio, Bishan, Hougang, Jurong West and Pasir Ris, among other areas. "We plan to set up 20 quick test centres across the island, to make it more convenient for staff in the identified sectors to go for testing," said HPB. The 20 centres include the 16 already set up. The board was responding to queries from ST about a tender it had put up on Government procurement portal GeBiz on June 23, looking for service providers to set up more quick test centres. It awarded the tender to two private healthcare firms, Minmed group and iGene Laboratory, on Thursday. When asked about how locations for setting up quick test centres are chosen, HPB said it considers site suitability and availability and that it works with various ministries, agencies and site owners to identify appropriate locations. Geographical spread, as well as the suitability and accessibility of the location to those who need to come for testing, are also considered. "The sites must also have spaces that are vacant to be used for the testing and large enough to put in place all the strict infection control measures to protect those being tested and the staff in the centre," said HPB. The board added that in setting up a centre, it puts in place specific measures to ensure proper traffic control, queue management, infection control and safe distancing to avoid overcrowding and disruption to traffic, and to protect those who visit the centre. At quick test centres, which were rolled out on June 21, workers in higher-risk settings can undergo the fast and easy test (FET) they have to do every 14 days. These tests became mandatory for staff in higher-risk settings from July 15. They can get tested at any of these centres islandwide or do self-swabs under the supervision of a trained staff member from their workplace. More on this topic   Related Story Businesses keen to send staff to quick Covid-19 test centres but waiting for more details   Related Story F&B and beauty sectors in Singapore adjust to mandatory Covid-19 testing Under the FET regime, antigen rapid tests are used that return results in about 30 minutes. People administer their own swabs under supervision at quick test centres. HPB said it expects most of the FET to be done by self-swabs supervised by an employer. "Supervision is necessary to ensure that the swab is performed correctly," it said. Quick test centres have been set up here to support small businesses whose staff need to be tested, but cannot organise such supervised testing on their own. Outlining the process, HPB explained that people tested at quick test centres will be guided by trained staff on how to self-administer antigen rapid tests. They will be informed of their result via SMS within the day. People with a positive or second invalid test result will be instructed to go for a confirmatory polymerase chain reaction (PCR) test, which is used to diagnose Covid-19 infection but takes longer to return results. The PCR test can take place at the nearest quick test centre or Swab and Send Home GP clinic. "The quick test centres have dedicated PCR stations to cater to these individuals. All infection prevention and control measures have been put in place to prevent transmission risk," said HPB. More on this topic   Related Story Testing for Covid-19: How S'pore is raising its game with DIY test kits and more   Related Story Mandatory testing to uncover hidden Covid-19 cases in S'pore the new normal: Expert   Related Stories:  Related Story S'pore suspends dining in, tightens Covid-19 curbs: What you need to know from July 22 Related Story Why is S'pore back to phase 2: Hospital capacity, community exposure to Covid-19 among considerations Related Story Spike in Covid-19 cases raises disturbing questions, but also carries lessons for S'pore Related Story KTV and Jurong Fishery Port Covid-19 clusters linked: Ong Ye Kung Related Story MOH to take 4-ring approach to contain Covid-19 spread from KTV cluster Related Story 'I'm old and dying, so what's the point of getting vaccinated?': Seniors yet to get the Covid-19 jab Related Story Covid-19 curbs in Seoul may be raised to highest level as new cases surge Related Story Indonesia expands nationwide Covid-19 curbs Related Story Made-in-Malaysia Covid-19 vaccine expected to be ready in 2024

Read More